DEA Temporarily Bans Two Potent Synthetic Nitazenes in Schedule I
Published Date: 8/15/2025
Rule
Summary
The DEA is temporarily putting two dangerous drugs, N-pyrrolidino metonitazene and N-pyrrolidino protonitazene, into Schedule I to keep everyone safe. This means strict rules and serious penalties now apply to anyone making, selling, or using these drugs. The change kicks in right away to stop harm before it happens.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Schedule I controls and penalties applied
The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I. That means the strict regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances now apply to anyone who manufactures, distributes, imports, exports, conducts research or instructional activities, performs chemical analysis, reverse distributes, or possesses these drugs.
Immediate action to protect public safety
The DEA says placing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I is necessary "to avoid imminent hazard to public safety," and the temporary scheduling is effective immediately. This action is intended to prevent harms from these two benzimidazole-opioids while the scheduling is in effect.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-15565 — Interim Enforcement Policy for Enforcement Discretion for General Licensee Adoption of Certificate of Compliance Holder-Generated Changes
The NRC is giving general license holders a break by not punishing certain rule slip-ups when they adopt changes made by the Certificate of Compliance holder. This temporary policy helps licensees adjust without stress while keeping safety in check. It affects anyone using these licenses and could save time and money during this transition period.
Next: 2025-15609 — Endangered and Threatened Species; Designation of Critical Habitat for Five Species of Threatened Indo-Pacific Corals; Correction
The National Marine Fisheries Service fixed a small mistake in their July 2025 rule about protecting five threatened Indo-Pacific coral species. They corrected the section numbers that point to important habitat areas, making sure everything matches up perfectly. This update helps keep coral protection clear and on track, with no extra costs or delays.